• Marc H Lebel, James D Kellner, E Lee Ford-Jones, Kyle Hvidsten, Edward C Y Wang, Vincent Ciuryla, Steve Arikian, and Roman Casciano.
• Division of Infectious Diseases, Sainte-Justine Hospital, University of Montreal, Quebec, Canada.
• Clin. Infect. Dis. 2003 Feb 1;36(3):259-68.

AbstractThe objective of this study was to evaluate the projected health benefits, costs, and cost-effectiveness of pneumococcal conjugate vaccination for infants and children aged <5 years in Canada. A health state model incorporating incidence, vaccine efficacy, costs, and transitional probabilities for the health states (well, meningitis, bacteremia, otitis media, pneumonia, and death) was constructed for a 10-year time horizon. Implementation of a pneumococcal conjugate vaccine program in Canada for each annual birth cohort of 340,000 persons observed over 10 years would be expected to save approximately 12 lives and 100,000 cases of pneumococcal disease over 10 years, resulting in total savings of $67 million (Canadian dollars [Can$]). Vaccination of healthy infants would result in net savings for society if the vaccine costs less than Can$50 per dose. Moreover, for a vaccine purchase price of Can$67.50, infant vaccination would cost society Can$79,000 per life-year gained. Pneumococcal conjugate vaccination is a potentially cost-effective means of pneumococcal disease prevention.

21 keywords...

hide…